Diversity of autoantibodies in patients with antimitochondrial antibody and their diagnostic value

S A McMillan,* Joan M Alderdice,† C M McKee,‡ A T Dawson,* M E Callender,§ T T Fulton,§ Margaret Haire‡

From the *Immunology Laboratory and the †Department of Histopathology, Belfast City Hospital, the Departments of ‡Medicine, ¶Microbiology and Immunobiology, The Queen’s University of Belfast, and the §Royal Victoria Hospital, Belfast, Northern Ireland

SUMMARY A retrospective analysis of clinical and laboratory features of 102 patients, whose sera contained antibody to mitochondria, showed that primary biliary cirrhosis was diagnosed in 50% of them. Immunofluorescence showed that the sera of the patients with primary biliary cirrhosis all had the M2 antimitochondrial antibody staining pattern. A new staining pattern, designated M2(1), which could be mistaken for the M2 pattern, was not found in any patients with either primary biliary cirrhosis or chronic active hepatitis.

Other serological variables such as antibody to mitochondria in IgM class, to multiple nuclear dots, and to the XR antigen, were associated with primary biliary cirrhosis, and taken in association with antimitochondrial antibody of M2 type, contribute to the diagnosis of the disease.

Although the aetiology of primary biliary cirrhosis is uncertain, it has many features of an autoimmune disease, including the presence of circulating immune complexes, abnormalities in the complement system and in cellular immunity, and the association with other autoimmune diseases, as well as the presence of various types of autoantibodies, especially antimitochondrial antibodies.1 The incidence of antimitochondrial antibody in patients with primary biliary cirrhosis, diagnosed on the basis of suggestive clinical history, cholestatic liver function tests, and a raised serum IgM value, has varied from 83–99%.2–5 The presence of antimitochondrial antibody is of uncertain importance, its specificity for primary biliary cirrhosis being between 11 and 49%.6–9 Antimitochondrial antibodies are also found in the sera of patients with other liver conditions, including chronic active hepatitis and cryptogenic cirrhosis and in patients with clinical but no biochemical evidence of liver disease.2 They are also found in the sera of patients who have rheumatological and endocrine autoimmune disorders and in subjects without any clinically apparent disease.4–10 Using indirect immunofluorescence, the M2 type of antimitochondrial antibody seems to be strongly associated with primary biliary cirrhosis,11 while other types (M1, M3, M5, M6) have been detected in the sera of patients with a wide variety of conditions.11–13 In addition, two antibodies to nuclear components have also been described in primary biliary cirrhosis—namely, antibody to centromere, which is a marker for the CREST syndrome,14 and an antibody that gives a staining pattern of nuclear dots15 or atypical discrete specks.16

The incidence of patients in the greater Belfast area, whose sera contained antimitochondrial antibody, increased from seven patients per 1000 patient samples in 1981 to 26 per 1000 patient samples in 1985, and most of these were referred from general medical units. This is probably a reflection of the increased use of autoimmune serological screening tests rather than a true increase in antimitochondrial antibody or an improved sensitivity of laboratory tests. The increasing incidence and uncertain clinical importance of antimitochondrial antibody prompted us to examine retrospectively the clinical and laboratory features of patients whose sera gave an antimitochondrial antibody staining pattern by indirect immunofluorescence and to investigate whether the presence of other autoantibodies and serum factors help in the diagnosis of primary biliary cirrhosis.

Material and methods

A retrospective investigation was made of the clinical and laboratory details of 102 patients from the greater Belfast area, whose sera, obtained over a period of eight years, contained antimitochondrial...
Diversity of autoantibodies in patients with antimitochondrial antibody

antibody at a titre of 1/20 or greater when tested by indirect immunofluorescence. The group comprised 91 women and 11 men with an average age at first detection of antimitochondrial antibody of 60 years. The sera from all of the patients were hepatitis B surface antigen (HBsAg) negative.

SEROLOGICAL STUDIES
Sera obtained from these patients were stored at −20°C. The serum samples were coded and re-examined (without knowledge of the clinical diagnosis, liver history, liver function tests, or serum IgM values) for the presence and titre of autoantibodies, including antimitochondrial antibody subtypes. Autoantibodies were detected by indirect immunofluorescence using various substrates, which included rat liver, kidney, stomach and heart, calf retina, and human thyroid gland, and the titres of autoantibodies were detected in IgG and IgM classes using fluorescein labelled antihuman immunoglobulin conjugates (Dako Ltd, UK). Antimitochondrial antibody subtypes, as defined by indirect immunofluorescence, were determined using composite tissue and fresh sections of rat kidney cut to show renal cortex and medulla, and the staining patterns were compared with patterns obtained with known antimitochondrial antibody types M1, M2, and M5 sera obtained from Dr GF Bottazzo, Immunology Department, Middlesex Hospital, London. HEp2 cells were used as substrate to detect the presence of various nuclear and cytoplasmic autoantibodies.\(^\text{15}\) Antibodies against soluble cellular antigens were detected and identified by counter-immunoelectrophoresis (CIE)\(^\text{17}\) using saline extracts of rabbit and calf thymus powder (Pelfreeze Biologicals, Arkansas, USA), a preparation of human spleen nuclei,\(^\text{18}\) and a cellular preparation of WI2 cells.\(^\text{19}\) The identification of antibodies detected was done using lines of identity with reference sera obtained from the Centres for Disease Control, Atlanta, USA. Antibody against XR and XH was detected by CIE, using extracts of rabbit thymus and human spleen as a source of XR and XH antigens, respectively.\(^\text{15}\)

CONTROL sera containing antibody to XR and XH and antibody giving a multiple nuclear dot pattern were obtained from Dr RM Bernstein. Concentrations of ds-DNA were assayed using the Farr technique (Anti-DNA kit assay, Amersham International, UK). Antibody to cardiolipin (VDRL antigen) was detected using the quantitative slide flocculation test (Wellcome Diagnostics, UK). Immunoglobulin M values were also assayed in the patients’ sera by radial diffusion using Nor-Partigen IgM plates (Behring Diagnostics, Hounslow, UK).

STATISTICS
The results were analysed using the independent \(t\) test, the Mann-Whitney \(R\)ank test, and the \(\chi^2\) test. The conventional level of significance, \(p < 0.05\), was used for all comparisons.

Results

CLINICAL DIAGNOSIS OF PATIENTS
Based on the clinical and biochemical findings at presentation and follow up and on the histological appearances of the needle liver biopsy specimens, primary biliary cirrhosis was diagnosed in 51 of the 102 patients, chronic active hepatitis in five, and cryptogenic cirrhosis in one patient. In a further six patients in whom liver biopsy was not carried out the clinical diagnoses were Gilbert’s syndrome, subclinical viral hepatitis, fulminant hepatic failure, and alcoholic liver disease in one patient and chronic liver disease of unknown aetiology in two patients. In 39 patients there was no clinical evidence of liver disease and various diagnoses were made (table 1).\(^\text{9}\)

ANTIMITCHONDRIAL ANTIBODIES AND SUBTYPES
The sera from the 102 patients contained antimitochondrial antibody, which gave three distinct staining patterns on rat tissues by immunofluorescence. The first corresponded to the M2 subtype described by Baum and Berg,\(^\text{11}\) giving strong fluorescence staining of distal tubules and a

<table>
<thead>
<tr>
<th>Clinical diagnosis</th>
<th>Total No</th>
<th>No with liver biopsy</th>
<th>Antimitochondrial antibody subtypes (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>M2</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>51</td>
<td>51</td>
<td>51 (100)</td>
</tr>
<tr>
<td>Chronic active hepatitis</td>
<td>5</td>
<td>5</td>
<td>5 (100)</td>
</tr>
<tr>
<td>Other liver disease</td>
<td>7</td>
<td>1</td>
<td>6 (86)</td>
</tr>
<tr>
<td>Scleroderma</td>
<td>4</td>
<td>0</td>
<td>2 (50)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>5</td>
<td>0</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Other connective tissue disease</td>
<td>5</td>
<td>0</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td>7</td>
<td>0</td>
<td>2 (29)</td>
</tr>
<tr>
<td>Miscellaneous disorders</td>
<td>15</td>
<td>0</td>
<td>10 (67)</td>
</tr>
<tr>
<td>No diagnosis</td>
<td>3</td>
<td>0</td>
<td>2 (67)</td>
</tr>
<tr>
<td>Total</td>
<td>102</td>
<td>57</td>
<td>86</td>
</tr>
</tbody>
</table>

Table 1  Clinical diagnosis of patients with different antimitochondrial antibody subtypes
slightly weaker staining of proximal tubules and collecting ducts, a granular appearance on rat hepatocytes, and strong uniform staining of rat gastric parietal cells (fig 1). The second pattern, designated M2(1), consisted of staining of only the distal tubules and collecting tubules, without staining of the proximal tubules (fig 2). The rat hepatocytes showed weak diffuse staining and the gastric parietal cells showed either weak or moderate staining. A third pattern, which corresponded to the M5 type of antimitochondrial antibody, as described by Labro et al.\textsuperscript{20} was identified by its characteristic appearance on rat kidney, in which proximal tubules in the outer cortex (P1 and P2) were much more brightly stained than the distal tubules, and there was no staining of gastric parietal cells (fig 3). The use of calf retina, rat heart, or Hep2 cells did not help discriminate between antimitochondrial antibody subtypes but provided good substrates for detecting antimitochondrial antibody. When the patients were subdivided by their antimitochondrial antibody types, 86 (84%) had the M2 type, six (6%) the M2(1) type, and 10 (10%) the M5 type (table 2). Although all patients who were diagnosed as having primary biliary cirrhosis or chronic active hepatitis had the M2 pattern, various other “non-liver disease” diagnoses made up the remainder of patients (24 of 86 with M2 antimitochondrial antibody. Of these 24 patients, eight had raised alkaline phosphatase and IgM activities and values, four had raised alkaline phosphatase activity only, and a further nine had raised IgM values only. The six patients whose sera gave antimitochondrial antibody pattern M2(1) had mostly endocrine disorders and none had primary biliary cirrhosis or chronic active hepatitis. Patients with the M5 pattern had a variety of mainly autoimmune conditions and did not have any apparent liver disease.

**FURTHER TESTS ON SERA FROM PATIENTS WITH M2 ANTIMITOCHONDRIAL ANTIBODY**

*Other antibodies*  
There was a higher incidence of antinuclear antibody and smooth muscle antibody in the group with primary biliary cirrhosis than the group with non-liver disease, although this difference was not significant (table 3). The use of Hep2 cultured cells as substrate increased the detection of antimitochondrial antibody and enabled different antinuclear antibody patterns to be observed: these included homogeneous nuclear, fine speckled nuclear, nuclear dot, multiple nuclear dot, centromere, homogeneous nucleolar, speckled nucleolar and rim nucleolar patterns. In the patients with the multiple dot pattern the number of dots per nucleus varied between five and 15, and there was a significant difference in the incidence of antibody to multiple nuclear dots in the patients with primary biliary cirrhosis compared with those without primary biliary cirrhosis (with primary biliary cirrhosis 21 of 51 or 41%; without primary biliary cirrhosis zero of 35, p = 0.004). A correlation was not found, however, between the number of dots per nucleus and any clinical or laboratory finding. Antibody to centromere was found in both the groups with and without primary biliary cirrhosis; most of these patients had scleroderma.\textsuperscript{14} Four different antibodies were detected which reacted against soluble cellular extracts. Antibodies to Ro and La were detected in similar numbers in patients with and without primary biliary cirrhosis, while antibody to XH was found in

---

**Fig 1** Immunofluorescence staining pattern of antimitochondrial antibody type M2 on rat kidney sections. Staining of both distal and proximal tubules. × 340. P = proximal convoluted tubules; D = distal convoluted tubules.

**Fig 2** Immunofluorescence staining pattern of antimitochondrial antibody type M2(1) on rat kidney sections. Staining of both distal tubules only. × 340. P = proximal convoluted tubules; D = distal convoluted tubules.

**Fig 3** Immunofluorescence staining pattern of antimitochondrial antibody type M5 on rat kidney sections. Staining of proximal tubules only. × 340. P = proximal convoluted tubules; D = distal convoluted tubules.
only one patient with primary biliary cirrhosis. The incidence of antibody to XR was significantly different between the groups (with primary biliary cirrhosis, eight of 51 or 16%; without primary biliary cirrhosis zero of 35, p = 0.034).

**Titre and immunoglobulin class of antimitochondrial antibody**

Although there was little difference between the geometric mean titre of the IgG class antimitochondrial antibody in the patients with and without primary biliary cirrhosis, there was a significant higher geometric mean titre of IgM class antimitochondrial antibody in the patients diagnosed with primary biliary cirrhosis compared with that of patients without primary biliary cirrhosis (p = 0.012), although these IgM titres were low in both groups (1/28 with primary biliary cirrhosis; 1/16 without primary biliary cirrhosis).

**Alkaline phosphatase activity and serum IgM value**

There was no significant difference between the incidence of patients with a raised alkaline phosphatase activity in either group (88% with primary biliary cirrhosis; 43% without, p = 0.08), and similarly, a significant difference was not seen between the incidence of patients with a raised IgM value (> 3 g/l) in both groups (86% with primary biliary cirrhosis; 51% without, p = 0.09).

**Discussion**

The clinical importance of antimitochondrial antibody is unknown. Triger et al. showed that most liver biopsy specimens from patients with antimitochondrial antibody but with no clinical signs of hepatocellular disease had normal histology or histology consistent with a diagnosis of primary biliary cirrhosis. Hodges et al. also found that four of seven liver biopsy specimens from patients with antimitochondrial antibody but with no evidence of primary biliary cirrhosis showed normal histology, in another two the histology was not consistent with primary biliary cirrhosis, and in only one were there features of primary biliary cirrhosis. In contrast, James et al. showed that all their patients with antimitochondrial antibody with normal liver function tests had liver biopsy histology consistent with primary biliary cirrhosis.

As liver biopsies were not carried out in patients without clinical or biochemical evidence of liver disease, investigations of other serological variables in the group of 86 patients with M2 antimitochondrial antibody were made. In our series antibody giving a multiple dot pattern on HEp2 cells was observed in 41% of patients with primary biliary cirrhosis but was absent in patients without primary biliary cirrhosis. Bernstein et al. described this pattern as numerous nuclear dots all the same size varying from two to 17 per cell, distinct from nucleoli, and different from centromere staining in that the dots were larger, fewer in number, and were not seen in mitotic cells. This staining was sensitive to trypsin digestion and resistant to RNAase and DNAase, indicating that the antigen is a protein. This pattern was found in 13% of 110 patients with primary biliary cirrhosis in their series but not in patients with HBsAg positive and negative chronic active hepatitis or in 60 control subjects. Cas-

---

**Table 2  Immunofluorescence intensities on rat composite tissue of various antimitochondrial antibodies found in sera of 102 patients studied**

<table>
<thead>
<tr>
<th>Antimitochondrial antibody subtype</th>
<th>Liver hepatocyte</th>
<th>Kidney</th>
<th>Stomach</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Proximal tubules 1</td>
<td>Proximal tubules 2</td>
<td>Proximal tubules 3</td>
</tr>
<tr>
<td>M2</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>M2(1)</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>M5</td>
<td>+</td>
<td>+ + +</td>
<td>+ + +</td>
</tr>
</tbody>
</table>

P1, P2, P3 = first, second, and third part of proximal tubule.

**Table 3  Incidence of autoantibodies in patients within M2 group**

<table>
<thead>
<tr>
<th>Patient groups (No in group)</th>
<th>Antinuclear* antibody</th>
<th>Smooth* muscle antibody</th>
<th>Antinuclear† antibody</th>
<th>Centromere†</th>
<th>Multiple† nuclear dots</th>
<th>Ro†</th>
<th>La‡</th>
<th>XR‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary biliary cirrhosis (51)</td>
<td>31</td>
<td>41</td>
<td>48</td>
<td>2</td>
<td>10</td>
<td>2</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td>Other liver disease (11)</td>
<td>18</td>
<td>36</td>
<td>27</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Non-liver disease (24)</td>
<td>15</td>
<td>19</td>
<td>29</td>
<td>12</td>
<td>12</td>
<td>8</td>
<td>8</td>
<td>0</td>
</tr>
</tbody>
</table>

* Detected by indirect immunofluorescence on rat tissue sections. 
† Detected by indirect immunofluorescence on HEp2 cells. 
‡ Detected by counterimmunoelectrophoresis using soluble tissue extracts.
sani et al. also described this pattern in 17% of patients with primary biliary cirrhosis and not in patients with other liver disease. This antibody has also been found in patients with primary biliary cirrhosis with the sicca syndrome, but as features of sicca syndrome were not investigated in our series we cannot substantiate this association. Antibody to a soluble cellular extract antigen XR obtained from saline extracts of rabbit thymus powder was detected in 16% of the patients with primary biliary cirrhosis and not in any other patients, and this antibody also seems to be a good marker for primary biliary cirrhosis, though Bernstein et al. also described this antibody in 24% of patients with HBsAg negative chronic active hepatitis. We found this antibody in only 4% of a series of 50 HBsAg negative patients with chronic active hepatitis (unpublished data).

The IgM class of antimitochondrial antibody was helpful in distinguishing between patients with and without primary biliary cirrhosis. A significantly greater number of patients with primary biliary cirrhosis had IgM class of antimitochondrial antibody of titre >1/20 than those without the disorder. It has been suggested that the specificity for primary biliary cirrhosis increases with antimitochondrial antibody titre, but in our study this was true for IgM titre but IgG did not help in discriminating between patients with and without primary biliary cirrhosis.

Although only 59% of patients with M2 type antimitochondrial antibody were diagnosed as having primary biliary cirrhosis, the presence within this group of IgM class antimitochondrial antibody, antibody giving a multiple nuclear dot pattern on HEp2 cells, and antibody to XR, enhanced the diagnostic value of M2 type antimitochondrial antibody for primary biliary cirrhosis.

We thank Mr SK Conlan for technical help and Mrs Maureen Collins for typing the manuscript.

References


Requests for reprints to: Dr SA McMillan, Immunology Laboratory, The Laboratories, Belfast City Hospital, Belfast BT9 7AD, Northern Ireland.